drugset / Trial / NCT04626726
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
NaSingle-groupOpen-labelTreatment
Summary
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic leukemia bridging allogeneic hematopoietic stem cell transplantation.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | — | — |
| Subject | CD19+CD22 CAR-T | Cell therapy | — | — |
| Subject | CD22 CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |